Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Zaleplon. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 1.00 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | GABRB3 | P28472 | 1/20 | 1.00 |
| ▸ | GABRA2 | P47869 | 1/20 | 1.00 |
| ▸ | GABRB2 | P47870 | 1/20 | 1.00 |
| ▸ | AOX1 | Q06278 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.45 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.39 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zaleplon SCHEMBL29375436 | 1.00 | KDM4E (1.00) | KDM4EMAPK1GABRA1GABRG2GABRB3 | |
| Zaleplon SCHEMBL5605771 | 1.00 | KDM4E (1.00) | KDM4EMAPK1GABRA1GABRG2GABRB3 | |
| Zaleplon SCHEMBL4727312 | 0.99 | KDM4E (0.98) | KDM4EMAPK1GABRA1GABRG2GABRB3 | |
| Zaleplon SCHEMBL4726630 | 0.99 | KDM4E (0.98) | KDM4EMAPK1GABRA1GABRG2GABRB3 | |
| Zaleplon SCHEMBL27637735 | 0.98 | KDM4E (0.96) | KDM4EMAPK1GABRA1GABRG2GABRB3 | |
| Zaleplon SCHEMBL4726658 | 0.96 | KDM4E (0.93) | KDM4EMAPK1GABRA1GABRG2GABRB3 | |
| Zaleplon SCHEMBL4726073 | 0.96 | KDM4E (0.93) | KDM4EMAPK1GABRA1GABRG2GABRB3 | |
| SCHEMBL3166147 | 0.93 | KDM4E (0.87) | KDM4EMAPK1GABRA1GABRG2GABRB3 | |
| SCHEMBL3164210 | 0.92 | KDM4E (0.86) | KDM4EMAPK1GABRA1GABRG2GABRB3 | |
| SCHEMBL3168939 | 0.91 | KDM4E (0.84) | KDM4EMAPK1GABRA1GABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 11246 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624037-B2 | Method of treating agitation, aggressive behavior, and impulse control disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-12624036-B2 | Method of treating post-traumatic stress disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| EP-4727627-A1 | AEROSOL-GENERATING DEVICE WITH IMPROVED AIRFLOW | Alexza Pharmaceuticals, Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| US-12594388-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | APTARGROUP, INC. (US) | 2026-04-07 | — | — | US | claimed |
| US-20260069593-A1 | METHODS FOR TREATING CANCER | AMGEN INC (US) | 2026-03-12 | — | — | US | claimed |
| US-20260027337-A1 | TRANSDERMAL DRUG DELIVERY DEVICES AND METHODS | MORNINGSIDE VENTURE INVESTMENTS LTD (MC) | 2026-01-29 | — | — | US | claimed |
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | claimed |
| US-12515030-B2 | Transdermal drug delivery devices and methods | MORNINGSIDE VENTURE INVESTMENTS LIMITED (MC) | 2026-01-06 | — | — | US | claimed |
| EP-3746138-B1 | ELECTRICAL CONDENSATION AEROSOL DEVICE | ALEXZA PHARMACEUTICALS INC (US) | 2025-12-10 | — | — | EP | claimed |
| WO-2025245294-A1 | NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR AGONISTS AND USES THEREOF FOR MODULATING WEIGHT GAIN | ENDEVICA BIO, INC. (US) | 2025-11-27 | — | — | WO | claimed |
| WO-2000038649-A1 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION DESIGNED TO PREVENT MISUSE AT THE EXPENSE OF A THIRD PARTY | SANOFI-SYNTHELABO (FR) | 2000-07-06 | — | — | WO | claimed |
| EP-1005863-A1 | Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof | SYNTHELABO (FR) | 2000-06-07 | — | — | EP | claimed |
| WO-2000025821-A1 | METHOD OF TREATING AND DIAGNOSING RESTLESS LEGS SYNDROME AND CORRESPONDING MEANS | HEDNER JAN (SE) | 2000-05-11 | — | — | WO | claimed |
| EP-0900086-A4 | ENHANCEMENT OF SLEEP WITH A GROWTH HORMONE SECRETAGOGUE | MERCK & CO INC (US) | 2000-01-12 | — | — | EP | claimed |
| EP-0900086-A1 | ENHANCEMENT OF SLEEP WITH A GROWTH HORMONE SECRETAGOGUE | Merck & Co., Inc. (US) | 1999-03-10 | — | — | EP | claimed |
| US-5714607-A | IMPROVED YIELDS ARE OBTAINED AT DECREASED REACTION TIMES BY ADDING WATER TO ACETIC ACID DURING REACTION OF 3-DIMETHYLAMINO-1-(3-N-ETHYL-N-ACETYLAMINOPHENYL)-2-PROPEN-1-ONE WITH 3-AMINOPYRAZOLE-4-CARBONITRILE | AMERICAN CYANAMID COMPANY (US) | 1998-02-03 | — | — | US | claimed |
| WO-1997041879-A1 | ENHANCEMENT OF SLEEP WITH A GROWTH HORMONE SECRETAGOGUE | MERCK & CO., INC. (US) | 1997-11-13 | — | — | WO | claimed |
| EP-0776898-A1 | Process improvement in the synthesis of N-[3-(3-cyanopyrazolo [1,5-a]pyrimidin-7-yl)phenyl]-N-ethyl-acetamide | American Cyanamid Company (US) | 1997-06-04 | — | — | EP | claimed |
| EP-0208846-B1 | [7-(3-Disubstituted amino)phenyl]pyrazolo[1,5-a]pyrimidines | AMERICAN CYANAMID CO (US) | 1993-11-18 | — | — | EP | claimed |
| US-4626538-A | [7-(3-disubstituted amino)phenyl]pyrazolo[1,5-a]pyrimidines | AMERICAN CYANAMID COMPANY (US) | 1986-12-02 | — | — | US | claimed |